Latest & greatest articles for diltiazem

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on diltiazem or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on diltiazem and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for diltiazem

1. Diltiazem

Diltiazem Top results for diltiazem - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for diltiazem The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Topical Minoxidil Versus Topical Diltiazem for Chemical Sphincterotomy of Chronic Anal Fissure: A Prospective, Randomized, Double-Blind, Clinical Trial

Topical Minoxidil Versus Topical Diltiazem for Chemical Sphincterotomy of Chronic Anal Fissure: A Prospective, Randomized, Double-Blind, Clinical Trial 29290068 2017 12 31 1432-2323 2017 Dec 31 World journal of surgery World J Surg Topical Minoxidil Versus Topical Diltiazem for Chemical Sphincterotomy of Chronic Anal Fissure: A Prospective, Randomized, Double-Blind, Clinical Trial. 10.1007/s00268-017-4449-x Anal fissure is a common anorectal problem causing severe pain and discomfort (...) to the patients. Chemical sphincterotomy has emerged as a noninvasive alternative to the surgical methods of fissure treatment. The objective of this study was evaluation of the efficacy and the adverse effects of topically applied minoxidil in chemical sphincterotomy of chronic anal fissure in comparison with topical diltiazem. A total of 88 patients with chronic anal fissure aged between 15 and 65 years were included in this double-blind, randomized clinical trial and were randomly assigned to either 0.5

EvidenceUpdates2018

3. Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure

Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure Sajid MS, Whitehouse PA, Sains P, Baig MK CRD summary The review concluded (...) that diltiazem and glyceryl trinitrate were equally effective in the initial healing of chronic anal fissure but diltiazem should be the preferred first line of treatment due to a lower incidence of headache and recurrent fissure. Notwithstanding some review limitations, these conclusions appear reasonable and the call for a further trial seems appropriate. Authors' objectives To compare diltiazem with glyceryl trinitrate for the non-surgical management of chronic anal fissure. Searching Cochrane Colorectal

DARE.2013

5. Simvastatin: dose limitations with concomitant amlodipine or diltiazem

Simvastatin: dose limitations with concomitant amlodipine or diltiazem Simvastatin: dose limitations with concomitant amlodipine or diltiazem Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Simvastatin: dose limitations with concomitant amlodipine or diltiazem From: Published: 30 October 2012 Therapeutic area: and The maximum recommended dose for simvastatin in conjunction with amlodipine and diltiazem is now 20 mg/day. Article date: October 2012 Pharmacokinetic (...) data Simvastatin is metabolised through the CYP3A4 pathway. Concomitant use of CYP3A4 inhibitors has the potential to increase exposure to simvastatin . Both amlodipine and diltiazem are substrates and inhibitors of CYP3A4 and therefore increase the plasma concentration (AUC0-24h) and maximum plasma concentration (Cmax) of simvastatin when they are co-administered. Studies have found that after 10 days of amlodipine (10 mg), the AUC0-24h of simvastatin and simvastatic acid following a single dose

MHRA Drug Safety Update2012

6. Intravenous diltiazem for the control of ventricular rate in patients with recent onset atrial fibrillation and left ventricular failure

Intravenous diltiazem for the control of ventricular rate in patients with recent onset atrial fibrillation and left ventricular failure BestBets: Intravenous diltiazem for the control of ventricular rate in patients with recent onset atrial fibrillation and left ventricular failure Intravenous diltiazem for the control of ventricular rate in patients with recent onset atrial fibrillation and left ventricular failure Report By: Dr Richard Parris - Consultant in Emergency Medicine Search checked (...) by Dr Simon Clarke - Consultant in Emergency Medicine, Frimley Park Hospital, Camberley, UK Institution: Royal Bolton Hospital, Lancs Date Submitted: 12th January 2005 Date Completed: 11th August 2009 Last Modified: 11th August 2009 Status: Green (complete) Three Part Question In a patient with [recent onset atrial fibrillation and left ventricular failure], can [diltiazem] [control the ventricular rate without worsening left ventricular function]? Clinical Scenario A 72-year-old woman with a past

BestBETS2009

7. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation

Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation 19487941 2009 06 18 2009 07 07 2013 11 21 1530-0293 37 7 2009 Jul Critical care medicine Crit. Care Med. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. 2174-9; quiz 2180 10.1097/CCM.0b013e3181a02f56 To compare (...) the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization. Randomized control trial. Acute emergency medical admission unit in a regional teaching hospital in Hong Kong. One hundred fifty adult patients with acute AF and rapid VR (>120 bpm). Patients were randomly assigned in 1:1:1 ratio to receive intravenous diltiazem, digoxin, or amiodarone for VR control

EvidenceUpdates2009

8. Diltiazem use in tacrolimus-treated renal transplant recipients

Diltiazem use in tacrolimus-treated renal transplant recipients Diltiazem use in tacrolimus-treated renal transplant recipients Diltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology The effects of using diltiazem as a first-line antihypertensive agent in renal transplant patients who received tacrolimus-based immunosuppressive treatment were evaluated. The mean average daily dose of diltiazem was 213.95 mg/day. Type of intervention Other: Management care (post-transplant). Economic study type Cost-effectiveness analysis. Study population The study population comprised patients who underwent renal transplantation. Of those

NHS Economic Evaluation Database.2004

9. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. 14734593 2004 01 21 2004 01 29 2016 10 17 1538-3598 291 3 2004 Jan 21 JAMA JAMA Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. 309-16 Many patients with chronic angina experience anginal (...) have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem and to determine times to angina onset and to electrocardiographic evidence of myocardial ischemia, effect on angina attacks and nitroglycerin use, and effect on long-term survival in an open-label observational study extension. A randomized, 3-group parallel, double-blind, placebo-controlled trial of 823 eligible adults with symptomatic chronic

JAMA2004

10. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin

Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin Kumana C R, Tong M K, Li C S, Lauder I J, Lee J S, Kou M, Walley T, Haycox A, Chan T M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Diltiazem, an antihypertensive agent, was used as a co-treatment to reduce the use of cyclosporin (i.e. Neoral) in renal transplant recipients. Neoral was a relatively new microemulsified cyclosporin formulation. Diltiazem was administered at a dose of 30 mg twice daily in patients weighing less than 60 kg, and at 60 mg twice daily

NHS Economic Evaluation Database.2003

11. Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting

Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary (...) patients who had undergone coronary artery bypass grafting (CABG) was examined. The pathway was based on the administration of oral amiodarone, rate and rhythm control, cardioversion, and anticoagulation. Rate control, if needed, was mainly achieved with intravenous diltiazem and less often with a beta-blocker. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients who had CABG and preoperative normal sinus

NHS Economic Evaluation Database.2002

12. Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery

Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery Amar D, Roistacher N, Rusch V W, Leung D H, Ginsburg I, Zhang H, Bains M S, Downey R J, Korst R J, Ginsberg R J Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined diltiazem as a prophylaxis for atrial arrhythmias after thoracic surgery. The dosage regimen comprised an intravenous loading dose of 0.25 mg/kg (50 mL) given over 30 minutes, followed by 0.1 mg/kg

NHS Economic Evaluation Database.2000

13. Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery

Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery Mooss A N, Wurdeman R L, Mohiuddin S M, Reyes A P, Sugimoto J T, Scott W, Hilleman D E, Seyedroudbari A Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of intravenous esmolol (a beta-blocker) or intravenous diltiazem (a calcium channel blocker) following open heart or valve replacement surgery was examined. Esmolol was given as a bolus of 500 microg/kg followed

NHS Economic Evaluation Database.2000

14. Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm

Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm Shapira O M, Alkon J D, Macron D S F, Keaney J F, Vita J A, Aldea G S, Shemin R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study focused on the use of two conduit vasodilators in the prevention of arterial conduit spasm after coronary bypass grafting (CABG). Patients received a 24-hour intravenous infusion of either nitroglycerin (0.1 microgram.kg-1.min-1) or diltiazem (0.1 mg/kg during 20 minutes and then 0.1 mg.kg-1.min-1), followed by 6 months

NHS Economic Evaluation Database.2000

15. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT)

Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) 10832825 2000 06 27 2000 06 27 2015 06 16 0140-6736 355 9217 2000 May 20 Lancet (London, England) Lancet Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research (...) Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) 1751-6 Diltiazem reduces non-fatal reinfarction and refractory ischaemia after non-Q-wave myocardial infarction, an acute coronary syndrome similar to the incomplete infarction that occurs after successful reperfusion. We postulated that this agent would reduce cardiac events in patients after acute myocardial infarction treated initially with thrombolytic agents-a clinical application previously unexplored with heart-rate-lowering

Lancet2000

16. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. 10972367 2000 09 14 2000 09 14 2015 06 16 0140-6736 356 9227 2000 Jul 29 Lancet (London, England) Lancet Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. 359-65 (...) Calcium antagonists are a first-line treatment for hypertension. The effectiveness of diltiazem, a non-dihydropyridine calcium antagonist, in reducing cardiovascular morbidity or mortality is unclear. We compared the effects of diltiazem with that of diuretics, beta-blockers, or both on cardiovascular morbidity and mortality in hypertensive patients. In a prospective, randomised, open, blinded endpoint study, we enrolled 10,881 patients, aged 50-74 years, at health centres in Norway and Sweden, who had diastolic

Lancet2000

17. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia.

Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. BACKGROUND: Tardive dyskinesia (TD) is a potentially disfiguring movement disorder of the orofacial region often caused by use of neuroleptic drugs. A wide range of strategies have been used to help manage TD and, for those who are unable to have their antipsychotic medication stopped or substantially changed, the calcium-channel blocking group of drugs (diltiazem, nifedipine, nimodipine, verapamil) has

Cochrane2000

18. Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris.

Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. 8551821 1996 02 21 1996 02 21 2015 06 16 0140-6736 346 8991-8992 1995 Dec 23-30 Lancet (London, England) Lancet Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. 1653-7 The effect of dihydropyridines in patients with unstable angina is discouraging. To find out the effect of the non-dihydropyridine-like (...) calcium-channel blocker diltiazem, a randomised, double-blind trial was conducted comparing diltiazem with glyceryl trinitrate, both given intravenously, in 129 patients with unstable angina. The endpoints were refractory angina or myocardial infarction, individually and as a composite endpoint. Refractory angina alone or together with myocardial infarction occurred significantly less commonly in the diltiazem group. While patients were on the trial drugs the numbers with refractory angina were 6 (10

Lancet1996

19. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients.

A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. 8417382 1993 01 26 1993 01 26 2016 11 23 0028-4793 328 3 1993 Jan 21 The New England journal of medicine N. Engl. J. Med. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. 164-70 Accelerated coronary artery disease is a major cause of late morbidity and mortality among heart-transplant recipients. Because calcium-channel (...) blockers can suppress diet-induced atherosclerosis in laboratory animals, we assessed the efficacy of diltiazem in preventing coronary artery disease in transplanted hearts. Consecutive eligible cardiac-transplant recipients were randomly assigned to receive diltiazem (n = 52) or no calcium-channel blocker (n = 54). Coronary angiograms obtained early after cardiac transplantation and annually thereafter were used for the visual assessment of the extent of coronary artery disease. The average diameters

NEJM1993

20. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy.

An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. 2407872 1990 04 03 1990 04 03 2016 10 17 0098-7484 263 11 1990 Mar 16 JAMA JAMA An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. 1507-12 This multicenter, factorial-design trial assessed the safety and additive (...) antihypertensive efficacy of a slow-release (SR) formulation of diltiazem hydrochloride given alone or in combination with hydrochlorothiazide for treatment of mild to moderate hypertension. After a 4- to 6-week placebo run-in period, 297 qualifying patients were randomized to receive placebo, 1 of 4 doses of diltiazem SR monotherapy, 1 of 3 doses of hydrochlorothiazide monotherapy, or 1 of 12 possible combinations of diltiazem SR and hydrochlorothiazide for 6 weeks. A dose-related reduction in blood

JAMA1990